头孢哌酮钠舒巴坦钠治疗小儿下呼吸道感染的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the efficacy of cefoperazone sodium and sulbactam sodium in children with lower respiratory tract infection.Methods A total of 70 children with lower respiratory tract infection admitted to our hospital from December 2016 to December 2017 were selected as the research subjects,the children were randomly divided into the control group and the observation group according to the No.ID of the children,with 35 cases in each group.The control group was treated with Azithormycin,while the observation group was treated with cefoperazone sodium and sulbactam sodium,the clinical effects of the two groups were compared and analyzed,and the bacterial clearance rate was tested.The incidence of adverse reactions was compared between the two groups.Results The total effective rate of the observation group(94.28%)was significantly higher than that of the control group(77.14%),the difference was statistically significant(P＜0.05).The average clearance rate ofStreptococcus pneumoniae,Klebsiella pneumoniae,Escherichia coli,Pseudomonas aeruginosa,Enterobacter cloacae,Proteus and other pathogens in the observation group (91.43%)were significantly higher than those in the control group(71.43%),the differences were statistically significant(P＜0.05).The incidence of adverse reactions in the observation group (0.00%)was significantly lower than that in the control group (5.71%)(P＜0.05).Conclusion Cefoperazone Sodium Sulbactam Sodium in the treatment of children with lower respiratory tract infection has a significant effect,can improve the bacterial clearance rate,reduce the incidence of adverse reactions.

Key words： Cefoperazone Sodium Sulbactam Sodium Azithromycin Lower respiratory tract infection in children Bacterial clearance rate Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Shu-ying

Cite this article:

WU Shu-ying. Clinical efficacy of cefoperazone sodium and sulbactam sodium in treatment of children with lower respiratory tract infection[J]. 中国当代医药, 2018, 25(29): 73-75.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I29/73

[1]	张晋雷，杨英阁，东建亭，等.急性下呼吸道感染患儿流行病学特征的调查分析[J].中华医院感染学杂志，2017，27（4）：907-910.
[2]	李建华，张力燕，季云瑞，等.呼吸内科不同区域下呼吸道感染耐药菌分布及耐药特征比较分析[J].重庆医学，2016，45（10）：1330-1333.
[3]	刘玲，赵弘卿，王昕华，等.呼吸重症监护病房下呼吸道感染病原菌种类、耐药状况及多重耐药菌感染危险因素分析[J].热带病与寄生虫学，2015，13（4）：215-218.
[4]	谢克开，关建强.降钙素原联合病原体检测在下呼吸道感染诊断中的应用价值[J].中国当代医药，2015，22（21）：108-110.
[5]	梅雪，汪怀芳，李静.头孢哌酮舒巴坦钠、利巴韦林治疗小儿支气管炎的疗效观察[J].中国现代医生，2013，51（18）：64-65.
[6]	蔡金龙，曲书强.肺炎支原体下呼吸道感染的发病机制及糖皮质激素的治疗作用[J].临床儿科杂志，2015，33（6）：597-599.
[7]	宁静，董汉权，任立歆.儿童下呼吸道感染病原菌分布及耐药性分析[J].中华医院感染学杂志，2014，24（5）：1260-1262.
[8]	曹丽云，赵琳.小儿下呼吸道感染的常见病原体及发病机制[J].中国微生态学杂志，2016，28（2）：246-248.
[9]	张康胜，邹明智，全国彪，等.下呼吸道感染采用不同抗生素方案治疗药学分析[J].北方药学，2014，11（1）：22-23.
[10]	孙秋风，严永东，陈正荣，等.下呼吸道感染性疾病7794例病原分布研究[J].中国实用儿科杂志，2014，29（3）：214-217.
[11]	萨日娜，王爱琼，孟红，等.降钙素原在儿童下呼吸道感染初始治疗中指导抗生素使用的意义[J].中国当代儿科杂志，2014，16（2）：211-213.
[12]	吴嵩，廖佑荣.3种头孢菌素类抗菌药物治疗下呼吸道感染的疗效及经济学探讨[J].中国医院用药评价与分析，2016，16（6）：760-762.
[13]	张英，安翠平，聂冰，等.不同配比头孢哌酮钠/舒巴坦对革兰阴性杆菌体外抗菌效果影响[J].临床误诊误治，2015，28（12）：102-104.
[14]	马花平.头孢哌酮钠/舒巴坦钠（舒普深）治疗老年人肺部感染的临床分析[J].中国当代医药，2016，23（24）：115-117.
[15]	李肇彦.头孢哌酮钠舒巴坦钠治疗下呼吸道感染的临床观察[J].中国当代医药，2013，20（33）：93-94.